MUC1 and Patent ductus arteriosus: In human PDA, MUC1, and COX-2/PGE2 pathways are highly activated and patients have high levels of MDSCs in the tumor, spleen, and blood, thus our data has high clinical relevance as future therapies can be designed to target MUC1 and COX-2 signaling.